Jaime Merchan, MD, discusses the efficacy results observed in the LITESPARK-013 trial of belzutifan in patients with advanced clear cell renal cell carcinoma.

ESPN analyst Randy Moss, who retired from the NFL in 2012 after 14 seasons, revealed that he is a “cancer survivor” and will ...

EU regulators recommend approval of Merck's drug Welireg for certain patients with VHL disease or advanced kidney cancer.

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...

Merck (MRK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion ...

The revenue for Uliledlimab is expected to reach an annual total of $33 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...

Nisevokitug is a monoclonal antibody commercialized by Novartis, with a leading Phase II program in Myelofibrosis;Post-Polycythemia Vera Myelofibrosis (PPV-MF);Post-Essential Thrombocythemia ...

Defective VHL protein is also present in most cases of advanced clear cell renal cell carcinoma (RCC), so a recommendation for belzutifan was issued to also cover this condition. The drug is indicated ...

Weill Cornell Medicine has received a four-year, $1.4 million grant from the U.S. Department of Defense to investigate a new therapeutic approach for ...

Phase 2 data suggest that metastectomy in renal cell carcinoma may be associated with delayed disease progression and ...

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.